LILRB2

Jounce Therapeutics to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022

Retrieved on: 
Thursday, July 28, 2022
GLOBE, LILRB2, PD-1, Therapy, Immune system, Tumor microenvironment, NASDAQ, Cancer, Gilead Sciences, Webcast, Patient, ICOS, ILT4, SELECT, CCR8, Macrophage, Investor, Pharmaceutical industry, Fourth, fifth, and sixth derivatives of position

Jounce Therapeutics' management team will host a webcast and live conference call at 8:00 a.m.

Key Points: 
  • Jounce Therapeutics' management team will host a webcast and live conference call at 8:00 a.m.
  • To access the conference call, please register here and please be advised to do so at least 10 minutes prior to joining the call.
  • The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the company's website at www.jouncetx.com.
  • Pimivalimab is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounces broader pipeline.

ImmunOs Therapeutics Raises $74 Million Series B Financing Round

Retrieved on: 
Tuesday, June 7, 2022
Degenerative disease, Saṃsāra, Iron Stone Strategic Capital Partners, Company, Series, LILRB1, ILT2, Doctor of Philosophy, Chairperson, Lightspeed Venture Partners, HLA, CEO, KIR, ILT4, Therapy, Patient, KIR3DL1, LILRB2, Immuno-psychiatry, Novartis, Immune system, Gimv, Antibody, Autoimmune disease, General partnership, Cancer, Vaccine, Pharmaceutical industry, MD, Speed of light

Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA June 7, 2022 ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of an oversubscribed Series B financing round totaling $74 million.

Key Points: 
  • Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA June 7, 2022 ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of an oversubscribed Series B financing round totaling $74 million.
  • "We are delighted to close this significant financing round led by a group of top-tier U.S. and European investors," said Sean R. Smith, CEO of ImmunOs Therapeutics.
  • ImmunOs Therapeutics AG leverages its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases.
  • ImmunOs is also developing antibodies to block the activation of specific HLA protein molecules associated with autoimmune diseases.

Jounce Therapeutics to Present at Upcoming Investor Conferences

Retrieved on: 
Tuesday, May 17, 2022
SELECT, Tumor microenvironment, CCR8, Webcast, Patient, ILT4, NASDAQ, PD-1, Therapy, Macrophage, Investor, Gilead Sciences, ICOS, LILRB2, Conference, ASCO, Immune system, Cancer, GLOBE, Pharmaceutical industry, Fourth, fifth, and sixth derivatives of position

Cowens 3rd Annual Oncology Innovation Summit: Insights for ASCO & EHA: A live presentation will take place virtually on Thursday, June 2, 2022 at 1:30 p.m.

Key Points: 
  • Cowens 3rd Annual Oncology Innovation Summit: Insights for ASCO & EHA: A live presentation will take place virtually on Thursday, June 2, 2022 at 1:30 p.m.
  • A webcast of each presentation can be accessed by visiting the Investors & Media section of Jounce website at https://ir.jouncetx.com/investor-overview .
  • Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform.
  • Pimivalimab is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounces broader pipeline.

Jounce Therapeutics Reports First Quarter 2022 Financial Results

Retrieved on: 
Thursday, May 5, 2022
COVID-19, U.S. Securities and Exchange Commission, Investment, ICOS, Immune system, NASDAQ, CCR8, GLOBE, Private Securities Litigation Reform Act, Neoplasm, LILRB2, Public expenditure, Safety, Research, Tumor microenvironment, Patient, Immunotherapy, Security (finance), Webcast, Macrophage, ILT4, Cancer, Annual report, NSCLC, LILRB4, Gilead Sciences, PD-1, Investor, Marketing, PD-L1, Conference, Intellectual property, ID, ILT3, Myelocyte, Therapy, Pharmaceutical industry, Fourth, fifth, and sixth derivatives of position, IND, SELECT

CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.

Key Points: 
  • First Quarter 2022 Financial Results:
    Cash position: As of March 31, 2022, cash, cash equivalents and investments decreased to $186.4 million, compared to $220.2 million as of December 31, 2021.
  • License and collaboration revenue: Jounce did not recognize any revenue during the first quarter of 2022.
  • Based on its current operating and development plans, Jounce reiterates its financial guidance for 2022.
  • Although Jounce believes that the expectations reflected in the forward-looking statements are reasonable, Jounce cannot guarantee such outcomes.

Jounce Therapeutics to Announce First Quarter 2022 Financial Results and Host Conference Call on Thursday, May 5, 2022

Retrieved on: 
Thursday, April 28, 2022
SELECT, PD-1, Immune system, Patient, Investor, GLOBE, Therapy, ID, Cancer, LILRB2, ILT4, ICOS, Webcast, Macrophage, NASDAQ, Tumor microenvironment, CCR8, Gilead Sciences, Pharmaceutical industry, Fourth, fifth, and sixth derivatives of position

Jounce Therapeutics' management team will host a live conference call and webcast at 8:00 a.m.

Key Points: 
  • Jounce Therapeutics' management team will host a live conference call and webcast at 8:00 a.m.
  • To access the conference call, please dial (866) 916-3380 (domestic) or (210) 874-7772 (international) and refer to conference ID 9072989.
  • The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the company's website at www.jouncetx.com .
  • Pimivalimab is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounces broader pipeline.

Immune-Onc Therapeutics Announces the Selection of Clinical Development Candidate IO-106, a First-in-Class Myeloid and Stromal Checkpoint Inhibitor Targeting LAIR1

Retrieved on: 
Wednesday, April 20, 2022
Oncology, Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, LILRB2, Drug development, Immunotherapy, CIRM, Biotechnology, California Institute for Regenerative Medicine, Investigational New Drug, Lymphocyte, NIH, IND, National Cancer Institute, Leukemia, LILRB4, Leukemia & Lymphoma Society, Twitter, Memorial Sloan Kettering Cancer Center, University, LLS, Research, CMML, PD-1, Food, Science, SITC, CA, Chronic myelomonocytic leukemia, White blood cell, ILT4, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, LAIR1, National, Patient, LinkedIn, Myelocyte, University of Texas at Austin, Company, Albert Einstein College of Medicine, ILT3, Society, Lymphatic system, AML, Regenerative medicine, Society for Immunotherapy of Cancer, Tumor microenvironment, Biology, Antibody, Collagen, NCI, Cancer, Record, Acute myeloid leukemia, Therapy, Survival, Vaccine

Immune-Onc Therapeutics, Inc. (Immune-Onc), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced the selection of IO-106, a first-in-class myeloid and stromal checkpoint inhibitor targeting the inhibitory receptor, LeukocyteAssociated ImmunoglobulinLike Receptor 1 (LAIR1), for clinical development.

Key Points: 
  • Immune-Onc Therapeutics, Inc. (Immune-Onc), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced the selection of IO-106, a first-in-class myeloid and stromal checkpoint inhibitor targeting the inhibitory receptor, LeukocyteAssociated ImmunoglobulinLike Receptor 1 (LAIR1), for clinical development.
  • LAIR1 is an immune inhibitory receptor expressed on lymphocytes and myeloid cells that correlates with worse survival in several cancers.
  • We are very excited about potential development opportunities for IO-106 and look forward to sharing our progress in the near future.
  • Immune-Onc Therapeutics, Inc. (Immune-Onc) is a private, clinical-stage cancer immunotherapy company dedicated to the discovery and development of novel myeloid checkpoint inhibitors for cancer patients.

Jounce Therapeutics to Participate in Raymond James LILRB/ILT Symposium: Deep Dive into “Myeloid Checkpoint” Therapeutics in Cancer

Retrieved on: 
Wednesday, April 20, 2022
LILRB2, Macrophage, Raymond James Financial, ICOS, SELECT, NASDAQ, CCR8, Gilead Sciences, PD-1, ILT4, GLOBE, Patient, Deep diving, Immune system, Tumor microenvironment, Therapy, Pharmaceutical industry, Fourth, fifth, and sixth derivatives of position, Cancer

CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will participate in a fireside chat at the Raymond James LILRB/ILT Symposium: Deep Dive into Myeloid Checkpoint Therapeutics in Cancer taking place virtually on Tuesday, April 26, 2022 at 1:00 pm ET.

Key Points: 
  • CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will participate in a fireside chat at the Raymond James LILRB/ILT Symposium: Deep Dive into Myeloid Checkpoint Therapeutics in Cancer taking place virtually on Tuesday, April 26, 2022 at 1:00 pm ET.
  • Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach.
  • Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform.
  • Pimivalimab is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounces broader pipeline.

Immune-Onc Therapeutics to Participate in the Raymond James LILRB/ILT Symposium on Myeloid Checkpoint Therapeutics in Cancer

Retrieved on: 
Tuesday, April 19, 2022
Pharmaceutical, Genetics, Health, Oncology, LILRB2, Drug development, Physiology, CIRM, Biotechnology, California Institute for Quantitative Biosciences, Raymond James Financial, NIH, National Cancer Institute, Leukemia, LILRB4, Leukemia & Lymphoma Society, Twitter, Memorial Sloan Kettering Cancer Center, University, LLS, Research, CMML, Immunotherapy, Food, White blood cell, ILT4, Chronic myelomonocytic leukemia, Regulation of tobacco by the U.S. Food and Drug Administration, LAIR1, National, Patient, LinkedIn, University of Texas at Austin, Company, Albert Einstein College of Medicine, ILT3, Lymphatic system, AML, Regenerative medicine, Tumor microenvironment, Biology, NCI, Record, University of Texas Southwestern Medical Center, Acute myeloid leukemia, California Institute for Regenerative Medicine, Therapy, Vaccine, Cancer

Immune-Onc Therapeutics, Inc. (Immune-Onc), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced the Company will present at the virtual LILRB/ILT Symposium: A Deep Dive into Myeloid Checkpoint Therapeutics in Cancer on Tuesday, April 26, 2022, at 2:00 PM EDT, hosted by Raymond James biotech analysts.

Key Points: 
  • Immune-Onc Therapeutics, Inc. (Immune-Onc), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced the Company will present at the virtual LILRB/ILT Symposium: A Deep Dive into Myeloid Checkpoint Therapeutics in Cancer on Tuesday, April 26, 2022, at 2:00 PM EDT, hosted by Raymond James biotech analysts.
  • As a private company and a leader in LILRB/ILT family of myeloid checkpoint target validation and therapeutics development, we are pleased to be invited to the Raymond James LILRB/ILT Symposium, said Charlene Liao, Ph.D., chief executive officer of Immune-Onc.
  • Immune-Onc was founded on groundbreaking science that first illuminated the role of the previously unexplored LILRB family of myeloid checkpoints in cancer.
  • Immune-Onc Therapeutics, Inc. (Immune-Onc) is a private, clinical-stage cancer immunotherapy company dedicated to the discovery and development of novel myeloid checkpoint inhibitors for cancer patients.

Immune-Onc Therapeutics Announces Preclinical and Clinical Poster Presentations for IO-108, a Novel Myeloid Checkpoint Inhibitor Targeting LILRB2 (ILT4), at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Retrieved on: 
Wednesday, March 9, 2022
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, AACR, National, Leukemia, American Association for Cancer Research, Twitter, Drug development, California Institute for Regenerative Medicine, CIRM, Research, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Memorial Sloan Kettering Cancer Center, LLS, AML, Cancer, Albert Einstein College of Medicine, NCI, University, LILRB2, CMML, Tumor microenvironment, National Cancer Institute, ILT4, Patient, Record, Acute myeloid leukemia, Chronic myelomonocytic leukemia, LAIR1, American Association, 2021 Essex County Council election, University of Texas at Austin, ILT3, NIH, Biology, LILRB4, Leukemia & Lymphoma Society, Immunotherapy, Regenerative medicine, Association, Food, Biotechnology, Adult, LinkedIn, Lymphatic system, Vaccine

The company aims to translate unique scientific insights in myeloid cell biology and immune inhibitory receptors to discover and develop first-in-class biotherapeutics that disarm immune suppression in the tumor microenvironment.

Key Points: 
  • The company aims to translate unique scientific insights in myeloid cell biology and immune inhibitory receptors to discover and develop first-in-class biotherapeutics that disarm immune suppression in the tumor microenvironment.
  • Immune-Onc has a differentiated pipeline with a current focus on targeting the leukocyte immunoglobulin-like receptor subfamily B (LILRB) of myeloid checkpoints.
  • Additional assets in Immune-Oncs pipeline include IO-106, a first-in-class antagonist antibody targeting LAIR1, and multiple undisclosed programs for solid tumors and hematologic malignancies.
  • Headquartered in Palo Alto, California, Immune-Onc has assembled a diverse team with deep expertise in drug development and proven track records of success at leading biotechnology companies.

Jounce Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

Retrieved on: 
Wednesday, March 2, 2022
Myelocyte, CCR8, Investment, ID, Quarter, Security (finance), RNA, Program, Webcast, COVID-19, Inflammation, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, SELECT, Macrophage, Therapy, Induction, Association, Ligand, Gilead Sciences, Society for Immunotherapy of Cancer, Immunoglobulin G, Public expenditure, Research, PD-L1, Investor, Annual report, American Association, LILRB4, Marketing, ICOS, Neoplasm, NSCLC, Immune system, NASDAQ, LILRB2, Patient, Immunotherapy, Science, Toxic epidermal necrolysis, Income, Safety, PD-1, Cancer, Conference, ILT4, CD4, Tumor microenvironment, Intellectual property, GLOBE, Pharmaceutical industry, Vaccine, Fourth, fifth, and sixth derivatives of position, IND

CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.

Key Points: 
  • Fourth Quarter and Full Year 2021 Financial Results:
    Cash position: As of December31, 2021, cash, cash equivalents and investments were $220.2 million, compared to $213.2 million as of December31, 2020.
  • License and collaboration revenue: No license and collaboration revenue was recognized during the fourth quarter of 2021.
  • General and administrative expenses: General and administrative expenses were $7.2 million for the fourth quarter of 2021, compared to $6.9 million for the fourth quarter of 2020.
  • Although Jounce believes that the expectations reflected in the forward-looking statements are reasonable, Jounce cannot guarantee such outcomes.